These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 19898430)
21. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
22. FDA's role in administering the Hatch-Waxman Act. Malkin BJ Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575 [No Abstract] [Full Text] [Related]
23. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION. Effingham AM Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613 [No Abstract] [Full Text] [Related]
24. Democrats prioritize pricing, generics and drug safety. Fox JL Nat Biotechnol; 2007 Feb; 25(2):150-1. PubMed ID: 17287735 [No Abstract] [Full Text] [Related]
26. FDA's role in making exclusivity determinations. Dickinson EH Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573 [No Abstract] [Full Text] [Related]
27. US biotech prepares to fight generic biologics. Reid B Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820 [No Abstract] [Full Text] [Related]
28. The History and Political Economy of the Hatch-Waxman Amendments. Lietzan E Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922 [No Abstract] [Full Text] [Related]
33. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
34. Takings issues in the approval of generic biologics. Yoo JC Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853 [No Abstract] [Full Text] [Related]
35. Similar concerns. Safety, costs among the issues to be weighed as FDA grapples with crafting an approval process for generic versions of biological medicines. Daly R Mod Healthc; 2011 Jul; 41(28):38-40. PubMed ID: 21853593 [No Abstract] [Full Text] [Related]
36. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
37. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box. Khullar D; Ohn JA; Trusheim M; Bach PB N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697 [No Abstract] [Full Text] [Related]
39. They are from the government and they really are here to help you. Woosley RL J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889 [No Abstract] [Full Text] [Related]
40. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]